Intravenous Administration of Nalbuphine

What is Nalbuphine?

Pre-Administration Steps

1. Visually inspect the solution for particulate matter or discoloration before use - discard if either is present.
2. Ensure naloxone (or nalmefene), resuscitative equipment, intubation supplies, and oxygen are immediately available at the bedside.
3. IV nalbuphine for anesthetic use must be administered only by personnel trained in IV anesthetic management and respiratory monitoring.
4. Assess the patient's: severity of pain, opioid-tolerance status, current medications (especially CNS depressants), and renal/hepatic function.

Dosage for IV Administration

For Analgesia (Pain Relief)

• Onset of action via IV: 2 to 3 minutes
• Duration of effect: 3 to 6 hours
• Plasma half-life: 5 hours (Miller's Anesthesia) / 2 to 3 h (Goodman & Gilman)

For Balanced Anesthesia (Supplement)

Pediatric Dosing (limited data)

• 0.1 to 0.2 mg/kg IV every 3 to 4 hours as needed for moderate-to-severe pain.

Step-by-Step IV Administration Technique

1. Prepare the dose - Draw up the calculated dose from the vial (10 mg/mL or 20 mg/mL) using aseptic technique.
2. Establish IV access - Confirm patent IV line with a running IV fluid (normal saline or 5% dextrose).
3. Slow IV push - Inject the dose slowly over 2 to 3 minutes for analgesic doses.
   • For anesthesia induction doses, administer over 10 to 15 minutes as per the prescribed rate.
4. Flush the line - Follow with 5-10 mL of compatible IV fluid to clear the line.
5. Monitor continuously post-administration:
   • Respiratory rate and depth
   • Oxygen saturation (SpO2)
   • Blood pressure, heart rate
   • Level of consciousness and sedation score
   • Pain score

Titration and Ongoing Therapy

• Titrate individually to achieve adequate analgesia with minimal adverse effects.
• Continually reassess pain control, adverse reactions, and risk for misuse or dependence.
• For IV PCA (patient-controlled analgesia): a basal rate of 1-3 mg/hr with demand doses of 1 mg every 15 minutes has been used.

Important Clinical Considerations

• Do NOT combine with pure mu-agonists (e.g., morphine, fentanyl) without a drug-free interval - nalbuphine can precipitate withdrawal or reverse analgesia in opioid-dependent patients due to its partial antagonist activity at mu receptors.
• CNS depressant interactions: Additive effects occur with benzodiazepines, other opioids, general anesthetics, phenothiazines, sedatives, hypnotics, and alcohol. Reduce doses of one or both agents when combined.
• Respiratory depression ceiling effect: Unlike pure opioids, doses beyond 30 mg produce no additional respiratory depression - this is a pharmacological safety advantage.
• Cardiovascular safety: Unlike pentazocine and butorphanol, nalbuphine does not increase cardiac index, pulmonary arterial pressure, or cardiac work - making it safer in cardiac patients. (Goodman & Gilman, Pharmacological Basis of Therapeutics)
• Reversal: Respiratory depression can be reversed with naloxone hydrochloride (IV). In physically dependent patients, titrate naloxone carefully with small doses to avoid precipitating a severe withdrawal crisis.

Common Adverse Effects to Monitor

• Sedation (most common)
• Nausea and vomiting
• Sweating, dizziness, vertigo
• Dry mouth, headache
• Respiratory depression (dose-dependent but plateaus at ~30 mg)
• At very high doses (>70 mg): psychotomimetic effects (dysphoria, racing thoughts, body image distortion)

• Miller's Anesthesia, 10th Edition, pp. 2877-2878
• Goodman & Gilman's The Pharmacological Basis of Therapeutics
• FDA Prescribing Information (Nubain/Nalbuphine HCl Injection, 2016)
• Palliative Care Network of Wisconsin - Nalbuphine Fast Fact